Indication
encorafenib in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation

Medicine details

Medicine name:
encorafenib (Braftovi)
SMC ID:
SMC2145
Pharmaceutical company
Pierre Fabre Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Advice due date:
Q3 2019
SMC meeting date:
Q2 2019
Patient group submission deadline:
04 March 2019